ERS Genomics with new CEO

John Milad, new ERS Genomics-CEO, brings over 25 years of experience as an executive leader, venture capitalist, and investment banker focused on the life sciences and medical technology sectors. As CEO of Quanta Dialysis Technologies for nearly a decade, he led the development and commercial launch of an portable haemodialysis system designed to transform the delivery of kidney care to patients. He drove market entry into the UK and US, while raising a record-breaking $245 million private funding round and building an extensive intellectual property estate of over 40 patent families. Prior to this, he served as CFO of Nitec Pharma, where he headed up finance and business development activities.

Milad also has significant experience as a venture investor, with previous roles as Partner and co-Head of Healthcare Ventures at Downing LLP and Investment Director at NBGI Ventures, as well as positions at Atlas Venture and Kirkland Investors.

Shaun Foy, Co-Founder and Chair of the Board of Directors, ERS Genomics, commented: “On behalf of the Board and executive team, I would like to welcome John as CEO. His experience uniquely positions him to lead ERS Genomics through the next stage of its development. I would also like to take the opportunity to thank Eric Rhodes for his leadership over the past eight years. During this time, ERS Genomics has been instrumental in providing access to the foundational CRISPR/Cas9 patent portfolio, enabling research and commercialisation across a broad range of applications within the life sciences, industrial biology, agriculture, and veterinary sciences sectors. We look forward to working with John as we continue to make this Nobel Prize winning gene editing technology widely available.”
Dublin-based ERS Genomics provides licensing to CRISPR/Cas9 technology for companies. ERS licenses these patents via its direct license from Emmanuelle Charpentier and now has nearly 150 licenses in place worldwide.